Ypsomed Holding AG
XMUN:OWX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Y
|
Ypsomed Holding AG
XMUN:OWX
|
CH |
|
Carsales.Com Ltd
ASX:CAR
|
AU |
|
L
|
LVMH Moet Hennessy Louis Vuitton SE
XHAM:MOH
|
FR |
|
Y
|
Yum! Brands Inc
XBER:TGR
|
US |
|
V
|
Vale Indonesia Tbk PT
XBER:XT3B
|
ID |
|
H
|
Halozyme Therapeutics Inc
F:RV7
|
US |
|
I
|
International Lithium Corp
SWB:IAH
|
CA |
|
Hilton Food Group PLC
OTC:HLTFF
|
UK |
|
AstraZeneca PLC
NYSE:AZN
|
UK |
|
Lem Holding SA
OTC:LMHDF
|
CH |
|
American Superconductor Corp
NASDAQ:AMSC
|
US |
|
W
|
Water Ways Technologies Inc
F:WWT
|
CA |
|
B
|
British American Tobacco PLC
DUS:BMT
|
UK |
|
F
|
FirstGroup PLC
OTC:FGROY
|
UK |
|
C
|
Canfor Corp
SWB:NKC
|
CA |
|
M
|
MetLife Inc
DUS:MWZ
|
US |
|
LATAM Airlines Group SA
F:LFL
|
CL |
|
Nestle SA
SIX:NESN
|
CH |
|
W
|
Wilmar International Ltd
XBER:RTHA
|
SG |
|
I
|
Impala Platinum Holdings Ltd
SWB:IPHB
|
ZA |
|
Senseonics Holdings Inc
F:6L60
|
US |
|
H
|
Hansoh Pharmaceutical Group Company Ltd
F:3KY
|
CN |
|
V
|
Viasat Inc
DUS:VS1
|
US |
|
M
|
MAG Silver Corp
LSE:0V56
|
CA |
Ypsomed Holding AG
Ypsomed Holding AG makes drug delivery devices that help patients inject medicines at home. Its core products include insulin pens, pen needles, autoinjectors, and pump systems for people who need regular injections, especially diabetes patients and other chronic-care users. The company also develops and sells connected devices and digital tools that help patients track treatment and use their medicines correctly. It sells these products mainly to pharmaceutical companies, healthcare providers, and patients. Some customers buy Ypsomed’s devices directly, while others use them as part of a drug company’s own treatment kit or brand. Ypsomed makes money by selling the devices themselves, supplying components and consumables, and in some cases by working with drug makers on customized delivery systems. What makes Ypsomed different is that it sits at the intersection of pharma and medical devices. It does not make the drugs; it makes the tools that deliver them safely and conveniently. That gives the company a recurring role in long-term treatments, where patients and drug companies need reliable injection hardware, replaceable parts, and easy-to-use systems.
Ypsomed Holding AG makes drug delivery devices that help patients inject medicines at home. Its core products include insulin pens, pen needles, autoinjectors, and pump systems for people who need regular injections, especially diabetes patients and other chronic-care users. The company also develops and sells connected devices and digital tools that help patients track treatment and use their medicines correctly.
It sells these products mainly to pharmaceutical companies, healthcare providers, and patients. Some customers buy Ypsomed’s devices directly, while others use them as part of a drug company’s own treatment kit or brand. Ypsomed makes money by selling the devices themselves, supplying components and consumables, and in some cases by working with drug makers on customized delivery systems.
What makes Ypsomed different is that it sits at the intersection of pharma and medical devices. It does not make the drugs; it makes the tools that deliver them safely and conveniently. That gives the company a recurring role in long-term treatments, where patients and drug companies need reliable injection hardware, replaceable parts, and easy-to-use systems.
Core Growth: Delivery Systems sales grew 21% to CHF 267 million, with strong auto-injector growth of 46% and core project revenues up 20%.
Profitability: EBIT for Delivery Systems reached CHF 87 million, with a margin of 32.4%. Reported EBIT included a CHF 75 million book profit from the Diabetes Care sale.
Strategic Focus: Ypsomed is now a pure-play self-injection device company after divesting non-core businesses, with no single client making up more than 15% of revenue.
Capacity Expansion: The company is investing CHF 1.5 billion to nearly triple capacity to 1 billion devices by early next decade, with new sites in Germany, China, and the U.S.
Guidance Unchanged: Management confirmed guidance for ~20% Delivery Systems sales growth and EBIT of CHF 190–210 million for the current year.
Strong Balance Sheet: Equity ratio sits at 67%, net debt/EBITDA at 0.3x, and operating cash flow for the core business was above CHF 140 million.
Future Ambitions: Midterm targets include CHF 900 million–1.2 billion in sales, CHF 280–340 million EBIT, and EBIT margins above 30%.
